Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3048% above fair value
$0.91−0.08 (-7.64%)
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Lineage Cell Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Lineage Cell Therapeutics's gross margin for the twelve months ending Mar 31, 2025 was 97.2%. For fiscal 2024 it was 96.5%, against 92.5% the year before. The highest annual figure on record is 99.3% in fiscal 2010.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 96.5% | +4.0 |
| FY2023 | Dec 31, 2023 | 92.5% | −2.6 |
| FY2022 | Dec 31, 2022 | 95.0% | +27.9 |
| FY2021 | Dec 31, 2021 | 67.2% | −11.8 |
| FY2020 | Dec 31, 2020 | 78.9% | −9.4 |
| FY2019 | Dec 31, 2019 | 88.3% | −5.7 |
| FY2018 | Dec 31, 2018 | 93.9% | −1.2 |
| FY2017 | Dec 31, 2017 | 95.1% | +1.2 |
| FY2016 | Dec 31, 2016 | 94.0% | +9.7 |
| FY2015 | Dec 31, 2015 | 84.3% | +0.2 |
| FY2014 | Dec 31, 2014 | 84.0% | +1.9 |
| FY2013 | Dec 31, 2013 | 82.1% | −6.8 |
| FY2012 | Dec 31, 2012 | 88.9% | −9.3 |
| FY2011 | Dec 31, 2011 | 98.2% | −1.0 |
| FY2010 | Dec 31, 2010 | 99.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 97.6% | +4.4 |
| Q4 FY2024 | Dec 31, 2024 | 94.6% | +6.9 |
| Q3 FY2024 | Sep 30, 2024 | 99.0% | +12.6 |
| Q2 FY2024 | Jun 30, 2024 | 96.9% | +0.8 |
| Q1 FY2024 | Mar 31, 2024 | 93.2% | −1.8 |
| Q4 FY2023 | Dec 31, 2023 | 87.7% | −6.9 |
| Q3 FY2023 | Sep 30, 2023 | 86.4% | −5.7 |
| Q2 FY2023 | Jun 30, 2023 | 96.1% | +0.8 |
| Q1 FY2023 | Mar 31, 2023 | 95.0% | −1.6 |
| Q4 FY2022 | Dec 31, 2022 | 94.7% | +12.1 |
| Q3 FY2022 | Sep 30, 2022 | 92.2% | +35.6 |
| Q2 FY2022 | Jun 30, 2022 | 95.3% | +19.7 |
| Q1 FY2022 | Mar 31, 2022 | 96.6% | +25.3 |
| Q4 FY2021 | Dec 31, 2021 | 82.5% | +14.6 |
| Q3 FY2021 | Sep 30, 2021 | 56.6% | −25.5 |
| Q2 FY2021 | Jun 30, 2021 | 75.6% | −5.0 |
| Q1 FY2021 | Mar 31, 2021 | 71.4% | −10.4 |
| Q4 FY2020 | Dec 31, 2020 | 67.9% | −22.2 |
| Q3 FY2020 | Sep 30, 2020 | 82.1% | +2.2 |
| Q2 FY2020 | Jun 30, 2020 | 80.6% | −5.7 |
| Q1 FY2020 | Mar 31, 2020 | 81.7% | −11.0 |
| Q4 FY2019 | Dec 31, 2019 | 90.1% | −3.1 |
| Q3 FY2019 | Sep 30, 2019 | 79.9% | −16.5 |
| Q2 FY2019 | Jun 30, 2019 | 86.3% | −9.6 |
| Q1 FY2019 | Mar 31, 2019 | 92.7% | +8.2 |
| Q4 FY2018 | Dec 31, 2018 | 93.1% | −6.9 |
| Q3 FY2018 | Sep 30, 2018 | 96.4% | −3.6 |
| Q2 FY2018 | Jun 30, 2018 | 95.8% | −4.2 |
| Q1 FY2018 | Mar 31, 2018 | 84.5% | −15.5 |
| Q4 FY2017 | Dec 31, 2017 | 100.0% | +0.0 |
| Q3 FY2017 | Sep 30, 2017 | 100.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 100.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 100.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 100.0% | – |
See a number that looks wrong?